.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Cipla
Cantor Fitzgerald
Accenture
Farmers Insurance
Baxter
QuintilesIMS
McKesson
Moodys
Deloitte

Generated: September 25, 2017

DrugPatentWatch Database Preview

Luitpold Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for LUITPOLD PHARMS INC, and what generic alternatives to LUITPOLD PHARMS INC drugs are available?

LUITPOLD PHARMS INC has fifteen approved drugs.

There are four US patents protecting LUITPOLD PHARMS INC drugs.

There are fifty-six patent family members on LUITPOLD PHARMS INC drugs in thirty countries.

Summary for Applicant: Luitpold Pharms Inc

Patents:4
Tradenames:15
Ingredients:15
NDAs:15
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Luitpold Pharms Inc
BUSULFAN
busulfan
INJECTABLE;INJECTION202259-001Dec 22, 2015APRXNoNo► Subscribe► Subscribe► Subscribe
Luitpold Pharms Inc
GEMCITABINE HYDROCHLORIDE
gemcitabine hydrochloride
INJECTABLE;INJECTION202031-001May 7, 2013APRXNoNo► Subscribe► Subscribe► Subscribe
Luitpold Pharms Inc
INJECTAFER
ferric carboxymaltose
INJECTABLE;INTRAVENOUS203565-001Jul 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Luitpold Pharms Inc
NANDROLONE DECANOATE
nandrolone decanoate
INJECTABLE;INJECTION091252-001Aug 30, 2010RXNoYes► Subscribe► Subscribe► Subscribe
Luitpold Pharms Inc
INJECTAFER
ferric carboxymaltose
INJECTABLE;INTRAVENOUS203565-001Jul 25, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Luitpold Pharms Inc
INJECTAFER
ferric carboxymaltose
INJECTABLE;INTRAVENOUS203565-001Jul 25, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Luitpold Pharms Inc
INJECTAFER
ferric carboxymaltose
INJECTABLE;INTRAVENOUS203565-001Jul 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Luitpold Pharms Inc
DEXMEDETOMIDINE HYDROCHLORIDE
dexmedetomidine hydrochloride
INJECTABLE;INJECTION203773-001May 12, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Luitpold Pharms Inc
OXALIPLATIN
oxaliplatin
INJECTABLE;IV (INFUSION)204378-001May 12, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Luitpold Pharms Inc
CALCIUM CHLORIDE 10%
calcium chloride
INJECTABLE;INJECTION209088-001Jul 27, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Luitpold Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,431,549Methods and compositions for administration of iron► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Luitpold Pharms Inc Drugs

Country Document Number Estimated Expiration
European Patent Office3081219► Subscribe
Canada2953964► Subscribe
Japan2006505638► Subscribe
Israel166747► Subscribe
South Korea20140117678► Subscribe
South Africa200504174► Subscribe
Portugal1554315► Subscribe
Cyprus1113387► Subscribe
Slovenia1554315► Subscribe
Australia2003278111► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Luitpold Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/018United Kingdom► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
00117Netherlands► SubscribePRODUCT NAME: DEXMEDETOMIDINE, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH IN FARMACEUTISCH OPZICHT AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZ ONDER DEXMEDETOMIDINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/2/02/033/001 20020830
C0003France► SubscribePRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
2008006Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
C/GB03/033United Kingdom► SubscribePRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
00125Netherlands► SubscribePRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
02/028Ireland► SubscribePRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
C0030Belgium► SubscribePRODUCT NAME: CHLORHYDRATE DE GEMCITABINE EQUIVALENT EN GEMCITABINE; NAT. REGISTRATION NO/DATE: 58 IS 88 F 12 19960606; FIRST REGISTRATION: NL RVG 17854 19950327
C/GB02/027United Kingdom► SubscribePRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
00071Netherlands► SubscribePRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Harvard Business School
AstraZeneca
Daiichi Sankyo
Chinese Patent Office
Cipla
McKesson
Express Scripts
Healthtrust
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot